Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML
This article was originally published in The Pink Sheet Daily
Executive Summary
Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.
You may also be interested in...
Australian ChemGenex Anticipates March Approval For First Product Omapro For Gleevec-resistant CML Patients
PERTH, Australia - Melbourne-headquartered ChemGenex will see its first product Omapro under review by U.S. FDA's Oncologic Drugs Advisory Committee Feb. 10 for patients with chronic myeloid leukemia who have failed to respond to Gleevec and who have the Bcr-Abl T315I mutation
Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise
Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.
Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise
Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.